
ãã¹ã¯ãã©ã³ãã 忝èŒè©Šéšã§ãææå·®ãªãã
ããã³ããŒã¯ã®6,000人以äžã察象ãšããã©ã³ãã 忝èŒè©Šéš(RCT)ã§ããã¹ã¯ãççšãã人ãšççšããªãã£ã人ã§COVID-19ã®ãŠã€ã«ã¹ææçã«ææå·®ãç¡ãã£ããšããè«æãçºè¡šãããã
ããã®è«æã«ã€ããŠè§£èª¬ããã
ç®æ¬¡
ïŒãRCTã§ææå·®ãªãã®æå³
ïŒããã®å®éšã¯ãã¹ã¯çŸ€ãæå©ã«ãã¶ã€ã³ãããŠãã
ïŒããã¹ã¯çŸ€ã®å®¶æã«ææãå€ãã£ãçç±
ïŒããŸãšã
ïŒãRCTã§ææå·®ãªãã®æå³
ãã¯ããã«ã©ã³ãã 忝èŒè©Šéš(RCT)ãšã¯äœãïŒã解説ããã
ãRCTã¯ã察象è
ãä»ã®æ¡ä»¶ã§ã¯çãããªãããã«æ¯ãåããããŠãããèŠå (ãã¹ã¯ççšïŒãçµæïŒææçïŒã«ã©ã圱é¿ãããã確ãããèšåºè©Šéšã ã
ãRCTã§çµ±èšçã«ææãªå·®ãèªããããã°ãç§åŠçã«å æé¢ä¿ã蚌æããããšãã§ããã
ãéã«RCTã§ææãªå·®ãåºãªããã°ããã®èŠå ïŒãã¹ã¯ïŒã¯çµæïŒææçïŒã墿žããåå ã§ã¯ãªããšèããããã
ãRCTã¯ããšããã³ã¹ã¬ãã«1ãšå»åŠçãšããã³ã¹ã®ãããã«äœçœ®ããã

ãã¬ãã«ïŒaã¯è€æ°ã®RCTãéããŠåæããã¡ã¿ã¢ãã·ã·ã¹ãã·ã¹ããããã¯ã¬ãã¥ãŒããã®ç ç©¶ã®ããã«äžã€ã®RCTã¯ã¬ãã«1bã ã
ãã¡ãªã¿ã«ããã¹ã¯ã®ãšããã³ã¹ãšããŠããã¡ãã£ã¢ãåãäžããåç©å®éšãå®éšå®€ã§ã®æ©æ¢°çãªå®éšã¯ãšããã³ã¹ã¬ãã«ïŒä»¥äžãèšåºçãªå æé¢ä¿ã¯ãã¡ãããçžé¢é¢ä¿ãã蚌æããããšã¯ã§ããªãããããã§ãå®éšè ãæ¡ä»¶ãæäœã§ãããããåèçšåºŠã«ãããªããªããšããããšã ã
ããããŸã§ããã¹ã¯ãšææçã«é¢ããŠåžäžã§äžè¬åžæ°ã察象ã«ããå€§èŠæš¡ãªRCTã¯ãªãã£ãããã®ç ç©¶ã¯äžçåã®è©Šã¿ã§ããããã®æçŸ©ã¯ãšãŠã倧ããã
ãç é¢ãªã©ã§å»çåŸäºè ã察象ãšããRCTã¯ããã€ããã£ããããããããã¹ã¯ã¯ææå·®ãåºããªãããéã«ææãå¢ããããéç床ãäžãããšããçµæã§ãã£ãã
ðã¡ã¿ã¢ããªã·ã¹ã§ãã¹ã¯å»çåŸäºè ã«å¹æãªãã
ðæ¥æ¬ã®å»çåŸäºè ã«ãã¹ã¯ã®ã¡ãªãããªããé çå¢å ã
ðãã¹ã¯ãå®¶æãžã®ææãæžãã广ç¡ããããããã¹ã¯çŸ€ã§ææãå€ãã£ãã
ãä»åã®RCTã¯ãåããŠãã¹ã¯ã®æå¹æ§ãç§åŠçã«èšŒæããããšæåŸ
ãããŠå§ãŸã£ãã
ãäŒç»ããç ç©¶è
ãã¡ã¯ãã¹ã¯ççšã«ãã£ãŠææçãååã«æžããšäºæ³ããŠããã
ããšããããçµæã¯ãææå·®ãªããã ã£ãã
ãäžå¿ããã¹ã¯çŸ€ã¯0.3%(1000人ã«3人)ææãå°ãªãã£ããšããçµæã§ã¯ãã£ããããã®å·®ä»¥äžã«éèŠãªããšã¯ãææå·®ãåºãªãã£ããããšã§ããã
ãææå·®ãªããšããã®ã¯ããã®0.3%ã®å·®ã§ãããçµ±èšçã«æå³ã®ããæ°åãšã¯èšãããããŸããŸããå¶ç¶ãã®å¯èœæ§ãé«ããšããããšã ãäŸãã°ããµã€ã³ããïŒåæ¯ã£ãŠïŒãšïŒãåºããšãããã ããããã®ãµã€ã³ãã¯ïŒä»¥äžãåºãããããšèšããã ãããïŒãã¡ããèšããªããã§ã¯100忝ã£ãŠå šéšïŒä»¥äžã ã£ããïŒãããã«ãããããšæãã ããã
ãçµæãå¶ç¶ãå¿ ç¶ããèŠæ¥µããçµ±èšçæŠå¿µããææå·®ãã§ãããPå€ãä¿¡é Œåºé(CI)ã§ç€ºãããã
ãPå€ã¯å°ããã»ã©ææãšãããææå·®ãèªããããã®ã¯å°ãªããšãP<0.05ã ã
ããã®ç ç©¶ã§ã¯På€ã¯ãP=0.38ã(æ¯çã§P = 0.33)ã ãããææå·®ã«ã¯ããããçšé ãããšã«ãªãã
ãä¿¡é Œåºé(CI)ã¯å·®ã®å Žåã¯ã0ããè·šããªããæ¯çã®å Žåã¯ãïŒããè·šããªãããšãææå·®ã®æ¡ä»¶ãšãªãã
ããã®ç ç©¶ã§ã¯å·®ã§ã¯ã95% CI, â1.2 to 0.4ããšã0ããè·šãã
ãæ¯çã§ã¯ã CI, 0.54 to 1.23ããšãïŒããè·šãã§ããã
ãã€ãŸããææå·®ãªãããšããããšã ããµã€ã³ããæ¯ã£ãŠïŒããå°ããæ°ãåºãããšãããããã«ãçµ±èšçã«ã¯ãã®ç ç©¶ã§ã-0.3ïŒ ããšåºãããšãå¶ç¶ã§ãããäœåºŠãåãæ¡ä»¶ã§å®éšãããå Žåã¯ãã¹ã¯çŸ€ã«ææãå€ãããšãååãããããšèããããã
ããã®ç ç©¶ã®çµæã¯ãããŸã§ãããã¹ã¯ãææãæžãããšããå æé¢ä¿ã¯åŠå®ãããããšèšãããšã ã
ãããã¯è«æã®äžã§ã®è°è«ãã©ããã£ãŠãèŠãããšã¯ã§ããªãç§åŠçäºå®ã§ããã
ããšãããããã¹ã¯ã®æå¹æ§ãä¿¡ããã人ã¯ãããèªãããããªãã人ã¯èª°ããèªåãä¿¡ãããããšã ããä¿¡ããããã§ãªãããšã¯ç¡èŠãããåŠå®ãããããåŸåããããããããèªç¥ãã確蚌ãã€ã¢ã¹ããšèšãã
ãäŸãã°ããã®è«æã®åºè«ã§ã芳å¯çãªãšããã³ã¹ã§ã¯ãã¹ã¯ãSARS-CoV-2ã®ææãæžããããšã瀺åãããŠããããªã©ãšæžãããŠããããããã®è«æã¯ãã¹ã¯ã®æå¹æ§ãåŠå®ããŠããªãããªã©ãšèšãã ã人ããããããã¯ãã®ç ç©¶ãè¡ãããèæ¯ã«éããªãã®ã«ãç ç©¶çµæããããããèªåã«éœåã®è¯ãæèšããç®ã«å ¥ããªããªãã®ã¯ã確蚌ãã€ã¢ã¹ãã®å žåã ãïŒãããã芳å¯çãšããã³ã¹ã¯çžé¢é¢ä¿ã¯ç€ºããŠãå æé¢ä¿ã¯ç€ºããªãïŒ
ããããå®ã¯åŒçšæç®ã®äžã«ã¯ãã¹ã¯ãææãæžãããããšã瀺ã芳å¯ç ç©¶ããç¡ãããã¹ã¯ãé¡ãçŽæ¥è§Šãããšãå¢ããããšããç ç©¶ãšæžããããšããç ç©¶(åŒçšæç®8,9)ãããã ãã ãïŒçŽæ¥é¡ãè§Šãæ©äŒãæžã£ã以äžã«ãã¹ã¯ãè§Šãæ©äŒãå¢ããŠããããšã ããïŒãã
ããã®ç ç©¶ã®åæãšãªã£ãããã¹ã¯ãææãæžããããšã瀺åãããŠããããšããã®ã¯æã蟌ã¿ã§ãããã瀺ã芳å¯çãšããã³ã¹ããå®ã¯ååšããªãã£ãããšã窺ããããïŒãããªãåŒçšããã¯ãã ïŒ
ïŒããã®å®éšã¯ãã¹ã¯çŸ€ãæå©ã«ãã¶ã€ã³ãããŠãã
ããã®ç ç©¶ã¯ãã¹ã¯ã®å¹æã蚌æããããã«è¡ããããã ãããã¹ã¯çŸ€ã§ææãæžãããã«æ§ã ãªå·¥å€«ããããŠããã
ã第äžã«ããµãŒãžã«ã«ãã¹ã¯(å»ççšã®ãã¹ã¯ïŒãçšããããŠããããšã ããã®å®éšã§ã¯ããã¹ã¯çŸ€ã®å¯Ÿè±¡è ã«å¯Ÿãã1ã¶æã®å®éšæéã«ã50æã®ãµãŒãžã«ã«ãã¹ã¯ãäŸçµŠããããã
ãããã«ãã¹ã¯çŸ€ã®å¯Ÿè±¡è ã¯ãã¹ã¯ã®é©åãªäœ¿ãæ¹ã®èª¬æãåããã
ãå®éã«ã¯ãåžäžã§å€ãã®äžè¬åžæ°ãççšããŠããã®ã¯ç¹°ãè¿ã䜿ããåžãã¹ã¯ã§ãããäœ¿ãæšãŠã®ãµãŒãžã«ã«ãã¹ã¯ã§ã¯ãªããé©åãªäœ¿ãæ¹ãæãããªãã
ãå»çåŸäºè
ã察象ã«ããç ç©¶ã§ã¯ãåžãã¹ã¯ã¯ãµãŒãžã«ã«ãã¹ã¯ã®13åããã¹ã¯ç¡ãã®ã³ã³ãããŒã«çŸ€ããææã«åŒåžåšææçãå€ãã£ãã

ããµãŒãžã«ã«ãã¹ã¯ãæ¯æ¥1å以äžã«äº€æãããã°ãåãåžãã¹ã¯ãäœæ¥ã䜿ãç¶ããŠããå®éã®äžè¬åžæ°ããã¯ããã«(13å以äžïŒæå©ãªæ¡ä»¶ã ã£ããšèããããããããã§ãææå·®ã¯åºãªãã£ãã®ã ã
ããããããç¹°ãè¿ã䜿ãåžãã¹ã¯ã ã£ããªãããã¹ã¯çŸ€ã®ææã¯ã¯ããã«å€ããªã£ãããšãäºæ³ãããã
ããŸããã®å®éšãè¡ãããã®ã¯ã4æã5æãã³ããŒã¯ã§ãã£ãããã³ããŒã¯ã¯å欧ã§ãããéŠéœã³ãã³ããŒã²ã³ã®ãã®ææã®æ¥ç §æéã¯14ã15æé以äžã«ãªãã
ãæ¡ä»¶ã«ãããããã¢ã¡ãªã«æ¿åºã®çºè¡šã§ã¯ãã³ãããŠã€ã«ã¹ã¯æ¥å ã§ïŒåã§å€±æŽ»ããã
æ¥ç §ã®å€ãææã«ã¯ææãåºãŸãã«ããã(çŸã«ååçã§ç¬¬ïŒæ³¢ãšããã4æãïŒæããç§ä»¥éã®æ¹ãPCRéœæ§è æ°ã¯ã¯ããã«å¢ããŠããïŒ
ãææãåºãŸãã«ãããã°ãå·®ãåºã«ãããªãããŸããã¹ã¯ã«ä»çãããŠã€ã«ã¹ãæ¥å
ã«åœããããšã«ãã£ãŠå€±æŽ»ãããããªãã
ãããç§ä»¥éãæ¥ç
§ã®å°ãªãææã«åæ§ã®å®éšããããŠãããªã倧ããªå·®ã§ãã¹ã¯çŸ€ã«ææè
ãåºãŠãããããããªãã
ãå®éã«ã9æä»¥éãã¹ã¯çŸ©ååã匷åããã¹ãã€ã³ã»ãã©ã³ã¹ã»ã€ã®ãªã¹ãªã©ã¯ãããããã¹ã¯çŸ©ååã匷åããŠä»¥éã«ææè
ãæ¥å¢ãåããã¯ããŠã³ã«è³ã£ãŠããããã¹ã¯ççšãå§ããªãã¹ãŠã§ãŒãã³ã§ãææè
ã¯å¢ããŠãããããã¹ã¯çŸ©åååœããã¯ããã«ãŸãã§ããã

ïŒããã¹ã¯çŸ€ã®å®¶æã«ææãå€ãã£ãçç±
ããã®ç ç©¶ã§ã¯ããäžã€è峿·±ãçµæãåŸãããã
ããã¹ã¯çŸ€ã®å®¶æã®æ¹ããã³ã³ãããŒã«çŸ€ã®å®¶æããææãå€ãã£ãã®ã ã
ãå€ãã£ããšèšã£ãŠã53:39ã§ãçµ±èšçã«ææãã©ããã¯ããããªãã
ãã ããå¶ç¶ãããããªãããå¿
ç¶çã«ãããªãçç±ãååšããã
ãããã¯ä»¥åã玹ä»ãããã¹ã¯ã®ããŠã€ã«ã¹ãæã¡åž°ãããã¯ã广ã ã

ã空æ°äžãªãã³ãããŠã€ã«ã¹ã¯3æéã§å€±æŽ»ããã®ã«ãã¹ã¯ã¯å
å€ãããŠã€ã«ã¹ãéãé·çããããçãã人ãåŒåžãããã³ã«ãæã§è§Šããã³ã«ã掻ãããŠã€ã«ã¹ãã°ãæãããšãå¯èœã«ããã®ã ã
ãå€ãããŠããããå®¶ã®ãŽãç®±ã§ãæºã®äžã§ããã±ããã®äžã§ããã¹ã¯ã¯äœæ¥ããŠã€ã«ã¹ãä¿åãç¶ããã°ãæãç¶ããã
ããããã广ãèããã°ããã¹ã¯çŸ€ã®å®¶æã«ææãå€ãã£ãã®ã¯åœç¶ãšãæããã
ïŒããŸãšã
ã以äžããã®ç ç©¶ãããã¹ã¯ççšãææãæžããææãªå¹æã¯åŠå®ãããã
ããããç§åŠçäºå®ã§ããã
ãWHOã»CDCã»ååœæ¿åºã»ç¥äºããããã«ç²åŸããæ
å ±åŒ±è
ããã®ä»ãã¹ã¯ãçããããããè
ãã©ãã ã倿°æŽŸã§ã©ããªã«åŸãé£ã°ããŠãã¹ã¯æå¹ãå説ããããšããç§åŠçæ ¹æ ã«ã¯ãªããªãã
ãããã°ãããããã¹ã¯ççšè ã®å®¶æã¯ææãªã¹ã¯ãå¢ããå¯èœæ§ãããããšã瀺åãããã
ã以äžãè«æã®æŠèŠã®åèš³ã
ãã³ããŒã¯äººã®ãã¹ã¯ççšè ã«ãããä»ã®å ¬è¡è¡ççæ¹æ³ã«ãã¹ã¯æšå¥šã远å ããããšã®ã³ãããŠã€ã«ã¹ææäºé²å¹æãã©ã³ãã 忝èŒè©Šéš
æ²èŒèªãAnnals of Internal Medicine
æ²èŒæ¥ã2020幎11æ18æ¥
èŠçŽ
èæ¯
芳å¯çç ç©¶ã§ã¯ãã¹ã¯ççšãCOVD-19ã®ææãæžããããšã瀺åãããŠããã芳å¯ãããçžé¢ãéææè
ã®ãã¹ã¯ççšã«ããã®ã(ææäºé²å¹æïŒãææãããã¹ã¯ççšè
ããã®ææãæžããã®ãïŒæææºã³ã³ãããŒã«ã«ããã®ãããããšãäž¡æ¹ãªã®ãã¯æããã§ãªãã
ç®ç
ãã¹ã¯ãäžè¬çã§ãªãå
¬è¡è¡ççã«æšå¥šãããŠããªãåœã§ãèªå®
å€ã§ãã¹ã¯ççšãæšå¥šããããšã§ãã¹ã¯ççšè
ã®ææãªã¹ã¯ãæžããã©ãããè©äŸ¡ããããšã
ãã¶ã€ã³
ã©ã³ãã 忝èŒè©Šéš(DANMARK-19[COVID-19ææã«å¯Ÿããé²åŸ¡ã®ããã®ãã¹ã¯ãè©äŸ¡ãããã³ããŒã¯äººç ç©¶])(ClinicalTraials.gov:NCT04337541)
ç¶æ³
ãã³ããŒã¯, 2020幎4æ~5æ
察象è
è·æ¥çã«ãã¹ã¯ã䜿çšãããèªå®
å€ã§1æ¥ã«3æé以äžéãã倧人ã
ä»å
¥
COVID-19ã«å¯ŸãããœãŒã·ã£ã«ãã£ã¹ã¿ã³ã¹ãåãããã«æšå¥šããå ããŠ50æã®ãµãŒãžã«ã«ãã¹ã¯ã®äŸçµŠãšãã®é©åãªäœ¿çšæ³ã®èª¬æãåãèªå®
å€ã§ä»äººãšããæã«ãã¹ã¯ççšãæšå¥šããã矀ãšããã¹ã¯ççšãæšå¥šãããªãã£ãçŸ€ãæ¯èŒããã
æž¬å®æ¹æ³
第ïŒçµæã¯æäœæ€æ»ãPCRããããã¯ç é¢ã§ã®èšºæã«ããïŒã¶ææç¹ã®ãã¹ã¯ççšè ã®SARS-CoV-2ææãšããã第ïŒçµæã¯ä»ã®åŒåžåšææçãŠã€ã«ã¹ã®PCRéœæ§çãšããã
çµæ
3030人ã®åå è ããã¹ã¯ççšçŸ€ãšããŠã2994人ãã³ã³ãããŒã«çŸ€(éççšçŸ€ïŒãšããŠã©ã³ãã ã«å²ãæ¯ããã4862人ãç ç©¶ãå®äºãããSARS-CoV-2ææã¯ãã¹ã¯ççšçŸ€ã®42人(1.8%)ãã³ã³ãããŒã«çŸ€ã®53人(2.1%)ã«èµ·ãã£ãã䞡矀éã®å·®ã¯-0.3% (95%ä¿¡é Œåºé, -1.2~0.4%ïŒP=0.38[ææå·®ãªã])ïŒãªããºæ¯0.82[ä¿¡é Œåºé0.54~1.23ïŒP=0.33[ææå·®ãªã])ã§ãã£ãããã®ç ç©¶ã«ã¯è€æ°ã®æ¬ é¥ããã远å ç ç©¶ãå¿ èŠãšãããããããªããããã®ç ç©¶ã§èгå¯ãããå·®ã¯çµ±èšçã«ææã§ãªãããã®95%ä¿¡é Œåºéã¯ãã¹ã¯ã®æšå¥šã¯ææã®46%æžå°ãã23%å¢å ã«çžåœããã
éç
決å®çã§ç¡ãçµæãåªå€±ããããŒã¿ããã¹ã¯ççšã®éµå®ã«å·®ãããããšãèªå® ã§ã®èªå·±æ€æ»çµæã®å ±åã§ããããšãç²æ€ã§ã¯ãªãããšããã¹ã¯ççšè ããä»äººãžã®ææã¯æžããããããããªãããšã®ç¡è©äŸ¡
çµè«
ä»ã®å ¬è¡è¡ççæ¹æ³ã«å ããŠãµãŒãžã«ã«ãã¹ã¯ã®ççšãæšå¥šããããšã¯ãææçãé«ããªããããçšåºŠãœãŒã·ã£ã«ãã£ã¹ã¿ã³ã¹ãåããããã¹ã¯ççšãäžè¬çã§ãªã瀟äŒã«ãããŠã50%以äžã®ç¢ºçã§SARS-CoV-2ã®ææçãæžãããªãã£ãããã®ããŒã¿ã¯ããçšåºŠã®äœãå人ææäºé²æ³ãšåçšåºŠã§ããã
äž»èŠãªè³éæº
Salling財å£(ãã³ããŒã¯ã®ïŒã€ã®ãããŒããå¶ãå°å£²äŒæ¥ãè³æ¬ã®19%ããã³ããŒã¯ã®é茞ã°ã«ãŒãA.P.Moller-Maersk Groupã«ããïŒ
https://en.sallinggroup.com/about-us/
ïŒè¿œèšïŒãã¡ãã¯ä»ã®æ¹ã®ãŸãšãã
ãç¹ã«æåŸã®ãšãããéèŠã§ãããã®è«æã¯çºè¡šãŸã§ã«äžæµå»åŠèªãè»äžŠã¿ãã®çµè«ããã«æ²èŒãæåŠããããšã話é¡ãšãªããŸããã
ããŸãã«ãããã®éèªã¯ãèŒããªãç¡è²¬ä»»ããéžæãããšèšããŸãã